Coronavirus Drug Discovery, Volume Three: Druggable Targets and In Silico Update presents comprehensive information on drug discovery against COVID-19. Chapters in Part One of this volume describe the various druggable targets and associated signaling pathways for effective targeting of SARS-CoV-2. In Part Two, chapters discuss the various computational approaches and in silico studies against SARS-CoV-2. Written by global team of experts, this book is an excellent resource that will be extremely useful to drug developers, medicinal chemists, pharmaceutical companies in R&D, research institutes in both academia and industry, and the National Library of Medicines and Health.
In addition, agencies such as the National Institutes of Health, Centers for Disease Control and Prevention, World Health Organization, European Medicines Agency, the US Food and Drug Administration, and all others involved in drug discovery against COVID-19 will find this book useful.
- Discusses the pathogenic mechanisms of SARS-CoV-2 and druggable targets
- Reviews the various signaling pathways associated with SAR-CoV-2 as possible druggable targets
- Presents computational approaches and in silico studies against SARS-CoV-2
Sprache
Verlagsort
Verlagsgruppe
Elsevier Science & Techn.
Dateigröße
ISBN-13
978-0-323-95579-9 (9780323955799)
Schweitzer Klassifikation
PART 1: DRUGGABLE TARGETS AND SIGNALING PATHWAYS 1. SARS-CoV-2 genome sequencing and promising druggable targets2. Signaling pathways implicated in SARS-CoV2 infection3. Roles of membrane lipids and lipid synthesis inhibitors in the propagation of coronavirus disease4. Potential Drugs in SARS-CoV-2 Treatment: Key Features and Mechanisms of Actions
PART 2: COMPUTATIONAL APPROACHES5. Application of computational tools for coronavirus drug discovery6. In silico Approaches in Drug Discovery for SARS-CoV-27. Application of molecular docking and dynamics tools in SARS-CoV-2 drug design: Ligand-protein interaction studies8. Molecular dynamic simulation with protein and detection of repurposable drugs for COVID-19 9. Computation-guided inhibitor screening against the nucelocapsid of SARS-CoV-2 10. In-silico insight into the interaction of 4-aminoquinolines with selected SARS-CoV-2 structural and non-structural proteins 11. In silico Evaluation of Anti-SARS-CoV-2 Activity of Punica granatum L. Phytochemicals12. In silico Investigation and Identification of Bioactive Compounds from Medicinal Plants as Potential Inhibitors against SARS-CoV-2 Cellular Entry
